ClinicalTrials.gg
RecruitingNCT06534684Updated Aug 2, 2024

The Cerebral and Cognitive Changes After Intermittent Theta Burst Stimulation (iTBS) Treatment for Depression

An interventional study of Intermittent Theta Burst Stimulation in Depression, Unipolar and Depression Moderate, sponsored by University Hospital of North Norway. Recruiting at 1 site in Norway. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-08-02.

Sponsored by University Hospital of North Norway · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Feb 2024, registered May 2024).
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
22 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Depressive Disorder with a site in Norway — 4 open to participants now, 5 under way, none of them phase 3. Depressive Disorder · Norway.

Planned enrollment
6th of 10
50 · median 52
Started
2024
the only one that year
No phase
7 of 15
3 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
University Hospital of North Norway

Among the 15 studies in Depressive Disorder with a site in Norway, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is one of 7 with no phase, and was the 15th registered.

Depressive Disorder

856 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

4 of the 15 studies in Depressive Disorder with a site in Norway are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 22 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Depressive Disorder with a site in Norway, or all of them as a file.
02

Study summary

The present project aims to assess the neurocognitive impact of a two-week once-a-day regimen of intermittent theta burst stimulation (iTBS) compared to sham iTBS, when targeting the left dorsolateral prefrontal cortex (LDLPFC) in clinically depressed outpatients. The study investigates the relationships between changes in cerebral measures and cognitive performance on an N-back task in relation to the antidepressive effect following iTBS.

Read the detailed description

The study is a randomized sham controlled double blind clinical trial in which the changes in cortical functions associated with the anti-depressive effect of two weeks of once-a-day neuronavigated iTBS over the left dorsolateral prefrontal cortex (LDLPFC) will be investigated in comparison to sham iTBS. Participants will be recruited prospectively, and the study is performed at a single university hospital. After written informed consent is obtained from eligible, volunteering patients, baseline measurements will be administrated, and the patient will be allocated to either sham or active iTBS once a day for 10 consecutive workdays. A total of three measurements will take place, namely at baseline prior to iTBS treatment, after two weeks with iTBS treatment (posttest) and four weeks after (follow-up). The primary outcome measures will be assessed from baseline to the posttest.

03

Conditions studied

  • Depression, Unipolar
  • Depression Moderate

Browse trials for

04

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must meet the diagnostic criteria of at least a moderate depression
  • The duration of the current depressive episode must have lasted more than 2 weeks but less than 2 years
  • Drug therapy must have been stable for the last three weeks prior to the first treatment day with iTBS
  • Patients must volunteer to provide , be able to follow the treatment schedule and have a satisfactory safety screening for iTBS and MRI

Exclusion criteria

Exclusion criteria:

  • The current depressive episode is in the mild range
  • The current episode fulfills the criteria for a major depressive episode requiring inpatient treatment and/or electroconvulsive therapy,
  • The current depressive episode is clearly triggered by grief or a recent major stressful life event
  • Bipolar disorder
  • Borderline personality disorder
  • Psychotic symptoms
  • Alcohol or substance abuse/addiction in the last 6 months
  • Current eating disorders
  • Obsessive- compulsive disorders
  • Post-traumatic stress disorder
  • A life-time medical history of seizure
  • Neurological or neurosurgical pathologies
  • Cardiac or systemic disease
  • Metallic prosthetic material or foreign objects (pacemakers, prosthetic eye equipment, etc.)
  • Autism
  • Pregnancy
  • Currently using of antipsychotic medication or benzodiazepines - or any medication that interferes with motor threshold excitability
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Intermittent Theta Burst Stimulation

    Stimulation will be performed with a Mag \& More PowerMag EEG 100 system with a double PMD70 p-cool (fluid-cooled) figure-of-eight coil.

    Device: Intermittent Theta Burst Stimulation

  • Placebo comparator
    Sham Intermittent Theta Burst Stimulation

    Sham stimulation will be performed by the Mag \& More PowerMag EEG 100 system double PMD70 p-cool figure-of-eight coil Sham system.

    Device: Intermittent Theta Burst Stimulation

Interventions

  • DeviceIntermittent Theta Burst Stimulation

    Intermittent Theta Burst Stimulation will be delivered with 120% of resting motor threshold with triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays).

06

What researchers measure

Primary outcomes

  1. Data from magnetic resonance imaging - white matter integrity

    Differences between groups when comparing intermittent theta burst stimulation versus sham intermittent theta burst stimulation in anatomical measures of cerebral white matter integrity quantified by fractional anisotropy measured by diffusion tensor imaging (DTI) obtained from magnetic resonance imaging (MRI).

    Time frame: Change from the pretest to the posttest after 10 treatments with iTBS, an average of 15 days

  2. Data from magnetic resonance imaging - cortical thickness

    Differences between groups when comparing intermittent theta burst stimulation versus sham intermittent theta burst stimulation in anatomical measures of thickness in cerebral gray matter thickness quantified by T1-weighted magnetic resonance imaging (MRI).

    Time frame: Change from the pretest to the posttest after 10 treatments with iTBS, an average of 15 days

  3. Data from magnetic resonance imaging - cerebral activity

    Differences between groups when comparing intermittent theta burst stimulation versus sham intermittent theta burst stimulation in cerebral activity quantified by blood-oxygen-level-dependent (BOLD) responses measured by functional resonance imaging (fMRI).

    Time frame: Change from the pretest to the posttest after 10 treatments with iTBS, an average of 15 days

Secondary outcomes

  1. Performance on a N-back cognitive test

    Differences between groups when comparing intermittent theta burst stimulation versus sham intermittent theta burst stimulation in behavioral performance on a cognitive task measuring working memory and executive performance when comparing intermittent theta burst stimulation versus sham intermittent theta burst stimulation.

    Time frame: Change from the pretest to the posttest after 10 treatments with iTBS, an average of 15 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymised data will be made available to other researchers when the study has ended.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Data will be published after completion of the study. The study protocol will be published as soon as possible.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jun 2025, 16 months after the start.

Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 16 months is below that.

Counting every sponsor, half of 276 studies reached it within 29 months; a quarter within 15 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2024
First posted
Aug 2, 2024
StartActual
Feb 12, 2024
Primary completionEst.
Jun 2025
CompletionEst.
Feb 12, 2029
Last update
Aug 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06534684
Collaborators
UiT The Arctic University of Norway
Responsible party
Per Aslaksen (Professor, University Hospital of North Norway) — Principal investigator
First posted
Aug 2, 2024
Start date
Feb 12, 2024
Primary completion
Jun 2025 (estimated)
Completion
Feb 12, 2029 (estimated)
Last update
Aug 2, 2024

Study contacts

Per M Aslaksen, PhD
Contact
per.aslaksen@unn.no
77649234 ext. +47
Marte C Ørbo, PhD
Contact
marte.c.orbo@uit.no
77645333 ext. +47

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion